Ionis Pharmaceuticals
IONS
313 hedge funds and large institutions have $4.69B invested in Ionis Pharmaceuticals in 2023 Q1 according to their latest regulatory filings, with 34 funds opening new positions, 87 increasing their positions, 128 reducing their positions, and 53 closing their positions.
69% more call options, than puts
Call options by funds: $17.2M | Put options by funds: $10.2M
25% more funds holding in top 10
Funds holding in top 10: 4 → 5 (+1)
0.23% less ownership
Funds ownership: 91.97% → 91.74% (-0.23%)
5% less capital invested
Capital invested by funds: $4.92B → $4.69B (-$222M)
7% less funds holding
Funds holding: 338 → 313 (-25)
32% less repeat investments, than reductions
Existing positions increased: 87 | Existing positions reduced: 128
36% less first-time investments, than exits
New positions opened: 34 | Existing positions closed: 53
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
+$61.1M |
| 2 |
BI
BVF Inc
San Francisco,
California
|
+$54M |
| 3 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
+$52M |
| 4 |
PAMS
Pictet Asset Management (Switzerland)
Geneva 73,
Switzerland
|
+$27.8M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$16.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$20.4M |
| 2 |
Goldman Sachs
New York
|
-$18.8M |
| 3 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$15.6M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$13.4M |
| 5 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
-$12.5M |
IONS Hedge Fund Activity: Q1 2023 in Review
313 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Ionis Pharmaceuticals (IONS) for Q1 2023, worth a combined $4.69B — down 4.5% from $4.92B a quarter earlier.
Sellers outnumbered buyers: 53 funds closed out of IONS and 34 opened new positions — a net loss of 19 holders — while 128 trimmed existing stakes and 87 added.
The largest buyer was Deep Track Capital, adding an estimated $61.1M. The largest seller was Renaissance Technologies, cutting an estimated $20.4M.
- 313 institutional investors held Ionis Pharmaceuticals (IONS) as of Q1 2023, down from 338 in Q4 2022.
- Funds reported $4.69B of Ionis Pharmaceuticals stock for Q1 2023, down 4.5% quarter-over-quarter.
- 34 funds opened new Ionis Pharmaceuticals positions in Q1 2023 and 53 closed out, a net change of -19 holders.
- The largest Ionis Pharmaceuticals buyer in Q1 2023 was Deep Track Capital, an estimated $61.1M added.
- The largest Ionis Pharmaceuticals seller in Q1 2023 was Renaissance Technologies, an estimated $20.4M sold.
Based on aggregated 13F filings for Q1 2023.